Journal › Topic
Biotechnology companies, drug development, and the venture economics of turning science into medicine.
4 entries
Sixty percent of American cancer deaths come from cancers no one screens for. GRAIL's Galleri blood test detects 50-plus types from a single draw, ...
For forty years, RAS was the most common cancer-causing protein in humans and the most famous undruggable target in oncology. On August 26, the FDA...
Moderna surged 177% after the first positive Phase 3 trial for an mRNA cancer therapy. Short sellers lost $5.5 billion. They were right that COVID ...
The FDA expanded Casgevy, the first CRISPR gene therapy, to children as young as two. The edit takes hours. The conditioning takes everything. To g...